Renaissance Technologies’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-213,814
| Closed | -$827K | – | 3998 |
|
|
2024
Q3 | $827K | Sell |
213,814
-2,000
| -0.9% | -$5.54K | ﹤0.01% | 2558 |
|
|
2024
Q2 | $501K | Sell |
215,814
-2,200
| -1% | -$5.68K | ﹤0.01% | 2689 |
|
|
2024
Q1 | $615K | Sell |
218,014
-3,600
| -2% | -$10.7K | ﹤0.01% | 2779 |
|
|
2023
Q4 | $705K | Sell |
221,614
-5,100
| -2% | -$17.4K | ﹤0.01% | 2596 |
|
|
2023
Q3 | $748K | Sell |
226,714
-4,445
| -2% | -$13.9K | ﹤0.01% | 2490 |
|
|
2023
Q2 | $763K | Buy |
231,159
+1,245
| +0.5% | +$4.39K | ﹤0.01% | 2639 |
|
|
2023
Q1 | $761K | Sell |
229,914
-3,200
| -1% | -$11.2K | ﹤0.01% | 2646 |
|
|
2022
Q4 | $842K | Sell |
233,114
-17,399
| -7% | -$114K | ﹤0.01% | 2632 |
|
|
2022
Q3 | $2.22M | Sell |
250,513
-19,599
| -7% | -$163K | ﹤0.01% | 1948 |
|
|
2022
Q2 | $2.08M | Sell |
270,112
-1,600
| -0.6% | -$12.8K | ﹤0.01% | 2157 |
|
|
2022
Q1 | $2.55M | Sell |
271,712
-5,400
| -2% | -$48.2K | ﹤0.01% | 2040 |
|
|
2021
Q4 | $1.92M | Sell |
277,112
-9,300
| -3% | -$78.1K | ﹤0.01% | 2181 |
|
|
2021
Q3 | $2.72M | Sell |
286,412
-19,345
| -6% | -$182K | ﹤0.01% | 1864 |
|
|
2021
Q2 | $3.06M | Sell |
305,757
-26,662
| -8% | -$297K | ﹤0.01% | 1954 |
|
|
2021
Q1 | $3.89M | Buy |
332,419
+23,607
| +8% | +$397K | ﹤0.01% | 1807 |
|
|
2020
Q4 | $11M | Buy |
308,812
+2,700
| +0.9% | +$46.6K | 0.01% | 1097 |
|
|
2020
Q3 | $4.23M | Sell |
306,112
-3,079
| -1% | -$46K | ﹤0.01% | 1668 |
|
|
2020
Q2 | $5.1M | Sell |
309,191
-3,900
| -1% | -$46.4K | ﹤0.01% | 1645 |
|
|
2020
Q1 | $2.66M | Sell |
313,091
-13,358
| -4% | -$187K | ﹤0.01% | 1904 |
|
|
2019
Q4 | $7.43M | Sell |
326,449
-440
| -0.1% | -$6.28K | 0.01% | 1627 |
|
|
2019
Q3 | $4.68M | Buy |
326,889
+1,615
| +0.5% | +$23.7K | ﹤0.01% | 1837 |
|
|
2019
Q2 | $4.33M | Buy |
325,274
+22,850
| +8% | +$345K | ﹤0.01% | 1890 |
|
|
2019
Q1 | $5.25M | Buy |
302,424
+73,423
| +32% | +$1.09M | ﹤0.01% | 1772 |
|
|
2018
Q4 | $3.13M | Buy |
229,001
+80,559
| +54% | +$1.42M | ﹤0.01% | 2006 |
|
|
2018
Q3 | $3.19M | Buy |
148,442
+103,431
| +230% | +$3.15M | ﹤0.01% | 2048 |
|
|
2018
Q2 | $1.93M | Buy |
45,011
+25,074
| +126% | +$1.15M | ﹤0.01% | 2276 |
|
|
2018
Q1 | $1.3M | Buy |
+19,937
| New | +$1.41M | ﹤0.01% | 2537 |
|
|
2017
Q3 | – | Sell |
-23,878
| Closed | -$1.58M | – | 3411 |
|
|
2017
Q2 | $1.58M | Buy |
23,878
+18,556
| +349% | +$2.3M | ﹤0.01% | 2384 |
|
|
2017
Q1 | $1.15M | Sell |
5,322
-10,878
| -67% | -$1.55M | ﹤0.01% | 2485 |
|
|
2016
Q4 | $1.5M | Sell |
16,200
-22,333
| -58% | -$2.52M | ﹤0.01% | 2362 |
|
|
2016
Q3 | $5.21M | Sell |
38,533
-52,078
| -57% | -$5.17M | 0.01% | 1575 |
|
|
2016
Q2 | $9.18M | Buy |
90,611
+9,867
| +12% | +$1.22M | 0.02% | 1203 |
|
|
2016
Q1 | $13.2M | Buy |
80,744
+74,419
| +1,177% | +$15.1M | 0.03% | 939 |
|
|
2015
Q4 | $2.07M | Sell |
6,325
-11,239
| -64% | -$3.66M | ﹤0.01% | 2088 |
|
|
2015
Q3 | $5.66M | Buy |
+17,564
| New | +$7.72M | 0.01% | 1300 |
|
|
2014
Q1 | – | Sell |
-3,133
| Closed | -$621K | – | 3051 |
|
|
2013
Q4 | $621K | Buy |
+3,133
| New | +$557K | ﹤0.01% | 2281 |
|
Renaissance Technologies's LUMO Position: Q4 2024 in Review
Renaissance Technologies sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 213,814 shares — an estimated $827K sold.
Renaissance Technologies first reported a position in LUMO in Q4 2013 and held it in 36 quarters. The position peaked at $13.2M in Q1 2016. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Renaissance Technologies reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Renaissance Technologies sold 213,814 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $827K.
- Renaissance Technologies first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 36 quarters.
- Renaissance Technologies's Lumos Pharma, Inc. Common Stock position peaked at $13.2M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.